Upload Avatar (500 x 500)
Yinzhong Ma
yz.ma@siat.ac.cn
Chinese, English
Guangdong
University of Chinese Academy of Sciences
Life Sciences
  • 2013-08--2016-07 Medical Doctor: Institute of Materia Medica, Chinese Academy of Medical Sciences
  • 2010-08--2013-07 Medical Master: Tianjin University of Traditional Chinese Medicine
  • 2005-08--2009-07 Bachelor of Science: Tianjin University of Traditional Chinese Medicine
  • 2017-07~2023-08 - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences - Associate Researcher
  • 2016-08~2017-06 - Tianjin Institute of Pharmaceutical Research New Drug Evaluation Co., Ltd. - Assistant Researcher
  • 2013-08~2016-07 - Institute of Materia Medica, Chinese Academy of Medical Sciences - Medical Doctor
  • 2010-08~2013-07 - Tianjin University of Traditional Chinese Medicine - Medical Master
  • 2005-08~2009-07 - Tianjin University of Traditional Chinese Medicine - Bachelor of Science
  • Beijing Science and Technology Award - Science and Technology Progress Award, Second Prize, Provincial Level, 2022
Animal models and therapeutic targets for cerebrovascular diseases
Development of cerebrovascular recanalization drugs based on nanomaterials
Blood-brain barrier dysfunction and central nervous system inflammation
  • Obesity-induced blood-brain barrier dysfunction: phenotypes and mechanisms, Third Author, Corresponding Author, 2024
  • Remote ischemic conditioning attenuates blood-brain barrier disruption after recombinant tissue plasminogen activator treatment via reducing PDGF-CC, Second Author, 2023
  • An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and reduces stroke patient-derived MMP-9 activity, Third Author, 2023
  • Activation of Wnt/Beta-Catenin Signaling Pathway as a Promising Therapeutic Candidate for Cerebral Ischemia/Reperfusion Injury, Sixth Author, Corresponding Author, 2022
  • Spatiotemporal lipidomics reveals key features of brain lipid dynamic changes after cerebral ischemia and reperfusion therapy, First Author, 2022
  • The Role of Immune Cells in Post-Stroke Angiogenesis and Neuronal Remodeling: The Known and the Unknown, First Author, 2021
  • The tissue origin of human mesenchymal stem cells dictates their therapeutic efficacy on glucose and lipid metabolic disorders in type II diabetic mice, First Author, 2021
  • Biological Functions and Regulatory Mechanisms of Hypoxia-Inducible Factor-1α in Ischemic Stroke, Second Author, 2021
Cerebrovascular Diseases Animal Models Therapeutic Targets Nanomaterials Recanalization Drugs Blood-Brain Barrier Dysfunction Central Nervous System Inflammation

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.